Newsfeeds Archive - Spark Newswire

1 minute read

Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting

April 25, 4:40 PM

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the

ADVM

1 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

April 23, 4:31 PM

Gainers 180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday’s after-market session. The market…

ABVC

2 minute read

Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?

By Vandana Singh

February 8, 3:59 PM

Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction.

ADVM

4 minute read

Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Avi Kapoor

February 5, 1:56 PM

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.

$SRM

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

February 5, 1:31 PM

Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) stock increased by 75.2% to $30.64 during Monday’s regular session. The company’s market…

ADVM

2 minute read

Why Adverum Biotechnologies Stock Is Trading Higher

By Erica Kollmann

February 5, 11:50 AM

Adverum will sell the shares at a price per share of $1.20, representing a premium of approximately 20% to its stock's 30-day volume-weighted average price, and the financing is expected to close on Feb. 8. Adverum anticipates the gross proceeds from the private placement to be approximately $127.5 million, before deducting any offering related expenses and are expected to be sufficient to fund the current operating plan into late 2025.

ADVM

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

February 5, 9:06 AM

Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) stock rose 60.1% to $28.0 during Monday’s pre-market session. The market value of…

ADVM

1 minute read

Adverum Biotechnologies To Present LUNA Preliminary Efficacy And Safety Data At The 47th Annual Meeting Of The Macula Society

By Benzinga Newsdesk

December 7, 5:18 PM

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary

ADVM

1 minute read

Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?

By Vandana Singh

November 6, 2:08 PM

Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology

ADVM

2 minute read

Adverum Biotechnologies Completes Enrollment Of Phase 2 LUNA Trial In Wet AMD

By Happy Mohamed

August 10, 5:11 PM

- LUNA 14-week data on aflibercept protein levels anticipated in the third quarter of 2023 and preliminary efficacy and safety data anticipated in the fourth quarter of 2023 - - Combined

ADVM